Company intelligence / Profile preview

Bridge Biotherapeutics

Pangyo, Gyeongi-do, Korea, Republic ofbridgebiorx.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company is developing BBT-877, a novel autotaxin inhibitor for fibrotic diseases including IPF, currently in Phase II. They are also developing BBT-207, a targeted therapy for NSCLC with EGFR C797S mutations.

Therapeutic areas: PulmonologyOncologyRare Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

6 assets

BBT-207

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Bridge Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bridge Biotherapeutics.

Explore the full profile